 
 
 
 
 
 
 
 
CSE vs. Epi[INVESTIGATOR_79181]030 [ZIP_CODE]  
July 15, 20 20 
 
 
 
 
 
 
 
 
 
[STUDY_ID_REMOVED]  
CSE v. Epi[INVESTIGATOR_79182]:  
The clinical procedure that will be used for research purposes is labor epi[INVESTIGATOR_79183] -epi[INVESTIGATOR_13873] (CSE) or epi[INVESTIGATOR_13873] (E).  
Study participants, prior to enrollment, will have already made a decisi on for themselves to use 
labor epi[INVESTIGATOR_79184] (decision made is one eligibility criteria). 
The study intervention, CSE or E, are both commonly used techniques in the initiation of 
epi[INVESTIGATOR_44187], but currently the utiliz ation of one or the other of these strategies is left to the 
discretion of the anesthesia clinician and is dictated primarily by [CONTACT_79196]. Thus an 
RCT will address this level of bias. Both CSE and E can be considered the standard of care for 
any laboring woman requesting labor epi[INVESTIGATOR_44187].  
BASELINE: At the first encounter, an assessment will include measurements of depression 
(EPDS), anxiety (STAI inventory), resiliency (ER 89), pain catastrophizing (PCS), perceived 
social support (MSPSS ) and pain (BPI -long form). For women recruited at the 3rd trimester visit, 
Quantitative sensory testing (QST) will be performed. The pain sensitivity test will involve the 
use of a small pad attached to the participant's arm. The thermal device will gradu ally heat up 
from the moment the participant feels the heat until the pain sensation becomes uncomfortable; 
the participant is instructed to tell investigators when to discontinue the test at the first moment 
of discomfort, at which time the test is stoppe d. The pain sensitivity test also includes pressure 
devices to assess pressure pain. These devices are widely and commonly used in clinical pain 
research. From these test, we will determine the participant's sensitivity profile which we will 
use in our stu dy analysis.  
To enhance recruitment, we will also approach women in early labor who have not yet received 
an epi[INVESTIGATOR_79185]. These women will answer  the aforementioned baseline surveys but will 
not participate in QST.  
Upon hospi[INVESTIGATOR_79186]: confirmation of term (>/= 37 weeks) planned 
vaginal delivery will occur. The participant will be randomized to one of two groups: combine d 
spi[INVESTIGATOR_1304] -epi[INVESTIGATOR_13873] (CSE) or epi[INVESTIGATOR_13873] (E). Randomization will occur by [CONTACT_79197]. At the 
moment of patient request for labor epi[INVESTIGATOR_44187], one sealed and opaque envelope 
containing the next assignment group will be opened. The envelopes will be located in a 
designated location in the anesthesia workroom of the birth center, and thus no delays in the 
laboring person's ability to receive the requested epi[INVESTIGATOR_79187]. Should any delay occur 
for any reason, no randomization will occur and th e patient will receive the epi[INVESTIGATOR_79188]. Initiation of each labor analgesic strategy will be standardized to 
minimize variability of analgesia, and is outlined on the study figure attached. Management of 
breakthrough pain will be standardized and will occur by [CONTACT_79198] ("supporting documentation").  
Throughout labor, pain will be assessed hourly using 100mm visual analog scales for both pain 
intensity and pain unpleasantness. Regard less of onset of labor (spontaneous or induction), 
hourly assessments are required to measure with accuracy and density the change in pain that is 
[STUDY_ID_REMOVED]  
CSE v. Epi[INVESTIGATOR_79189], in response to both the progress of labor and any 
changes in respon se to medications via the epi[INVESTIGATOR_79190]. For the entire labor, labor variables 
will be recorded, including sterile vaginal exam (SVE) at the time of epi[INVESTIGATOR_79191], duration 
of labor (time from admission to unit until time of delivery), number of man ual epi[INVESTIGATOR_79192], total dose of local anesthetic and epi[INVESTIGATOR_79193], and the outcome 
of labor -- both maternal (normal spontaneous vaginal delivery, instrumental delivery, cesarean 
delivery, perineal lacerations, total oxytocin dos e requirements) and neonatal (sex, Apgar scores, 
need for resuscitation, need for neonatal ICU). Study procedures will continue should the need 
arise for a cesarean delivery or if there are any other complications to the pregnancy/fetus.  
Postpartum measur ements will be made as follows:  
Postpartum day 0 -2: Within 2 days we will measure co -variates of pain (BPI [CONTACT_69506]), 
breastfeeding (yes/no) and perceived stress (PSS).  
At 6 weeks, we will measure the primary outcome of EPDS score as well as co -variates 
including pain (BPI [CONTACT_69506]), maternal  infant attachment (MPAS), parenting self -efficacy (PMP -
SE), child development (ASQ -3), and breastfeeding (yes/no) (i.e. "Are you currently 
breasfteeding? Yes or no.") A margin of 7 days around the 6 week postpartum mark will be 
allowed for the patient to respond.  
At 3 months, we will assess breastfeeding (Y/N), Depression (EPDS), Pain (BPI â€“ Short Form), 
Mother -infant attachment (MPAS), Parenting self -efficacy (PMP -SE), Child development (ASQ -
3). A margin of 7 days around the 3 month postpartum mark will be allowed for the patient to 
respond.  
Should a participant not respond to follow -up surveys at the specified time, we will exclude their 
data from analysis; depending upon the volume and nature of such missing data, we reserve the 
ability to impute missi ng data if MAR or MNAR.  
Interactions with participants will occur in person, electronically (email), or by [CONTACT_648]. 
Investigators will consent participants to retain the ability to re -contact [CONTACT_79199] a future 
date for follow -up questions.  
 
 
 
 
 
 
 
 
[STUDY_ID_REMOVED]  
CSE v. Epi[INVESTIGATOR_79194]:  
The estimat ed incidence of [COMPANY_003] in U.S. American women is 20%, commensurate with estimates 
of institutional rates of [COMPANY_003] at Magee -Womens Hospi[INVESTIGATOR_307].36 As a pi[INVESTIGATOR_2268], we will target 10% of the 
sample required for a full study. The primary outcome is risk for [COMPANY_003], measured b y EPDS score 
at the [ADDRESS_86559] 80% 
power to detect a 10% reduction in [COMPANY_003] symptoms at a significance level of 5% (two -tailed). 
With an optimistic estimated attrition of 15%, a full tr ial would aim to enroll 454 participants, 
227 in each group. For this pi[INVESTIGATOR_79195] a sample of 23 patients in each group (total 46), to 
yield 10% of the full study sample. Given a yet unknown attrition rate, we estimate that study 
procedures in a m aximum of [ADDRESS_86560] feedback.  
 
Linear regres sion will be used to examine the relationship between EPDS scores and treatment 
group, both over time  in participants and by [CONTACT_19313].  The relationship betwee n pain and EPDS will 
also be examined using lin ear regression. T-tests, linear regression, and chi -squared tests will be 
used, where appropriate, to examine the  relationships  between treatment group and pain, infant 
attachment, infant development, and breastfeeding . 